Literature DB >> 34232981

Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.

Bing Z Carter1, Wenjing Tao1, Po Yee Mak1, Lauren B Ostermann1, Duncan Mak1, Gerard McGeehan2, Peter Ordentlich2, Michael Andreeff1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34232981      PMCID: PMC8554651          DOI: 10.1182/blood.2021011917

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  25 in total

1.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.

Authors:  Jolanta Grembecka; Shihan He; Aibin Shi; Trupta Purohit; Andrew G Muntean; Roderick J Sorenson; Hollis D Showalter; Marcelo J Murai; Amalia M Belcher; Thomas Hartley; Jay L Hess; Tomasz Cierpicki
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

2.  Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction.

Authors:  Dmitry Borkin; Szymon Klossowski; Jonathan Pollock; Hongzhi Miao; Brian M Linhares; Katarzyna Kempinska; Zhuang Jin; Trupta Purohit; Bo Wen; Miao He; Duxin Sun; Tomasz Cierpicki; Jolanta Grembecka
Journal:  J Med Chem       Date:  2018-05-23       Impact factor: 7.446

3.  Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.

Authors:  Derek Yecies; Nicole E Carlson; Jing Deng; Anthony Letai
Journal:  Blood       Date:  2010-03-02       Impact factor: 22.113

4.  Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.

Authors:  Dmitry Borkin; Shihan He; Hongzhi Miao; Katarzyna Kempinska; Jonathan Pollock; Jennifer Chase; Trupta Purohit; Bhavna Malik; Ting Zhao; Jingya Wang; Bo Wen; Hongliang Zong; Morgan Jones; Gwenn Danet-Desnoyers; Monica L Guzman; Moshe Talpaz; Dale L Bixby; Duxin Sun; Jay L Hess; Andrew G Muntean; Ivan Maillard; Tomasz Cierpicki; Jolanta Grembecka
Journal:  Cancer Cell       Date:  2015-03-26       Impact factor: 31.743

5.  NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model.

Authors:  M Mallardo; A Caronno; G Pruneri; P R Raviele; A Viale; P G Pelicci; E Colombo
Journal:  Leukemia       Date:  2013-04-15       Impact factor: 11.528

6.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Authors:  Brunangelo Falini; Cristina Mecucci; Enrico Tiacci; Myriam Alcalay; Roberto Rosati; Laura Pasqualucci; Roberta La Starza; Daniela Diverio; Emanuela Colombo; Antonella Santucci; Barbara Bigerna; Roberta Pacini; Alessandra Pucciarini; Arcangelo Liso; Marco Vignetti; Paola Fazi; Natalia Meani; Valentina Pettirossi; Giuseppe Saglio; Franco Mandelli; Francesco Lo-Coco; Pier-Giuseppe Pelicci; Massimo F Martelli
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

7.  Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.

Authors:  Daniel A Pollyea; Brett M Stevens; Courtney L Jones; Amanda Winters; Shanshan Pei; Mohammad Minhajuddin; Angelo D'Alessandro; Rachel Culp-Hill; Kent A Riemondy; Austin E Gillen; Jay R Hesselberth; Diana Abbott; Derek Schatz; Jonathan A Gutman; Enkhtsetseg Purev; Clayton Smith; Craig T Jordan
Journal:  Nat Med       Date:  2018-11-12       Impact factor: 53.440

8.  Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.

Authors:  Aibin Shi; Marcelo J Murai; Shihan He; George Lund; Thomas Hartley; Trupta Purohit; Gireesh Reddy; Maksymilian Chruszcz; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

9.  The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:  Elizabeth C Townsend; Mark A Murakami; Alexandra Christodoulou; Amanda L Christie; Johannes Köster; Tiffany A DeSouza; Elizabeth A Morgan; Scott P Kallgren; Huiyun Liu; Shuo-Chieh Wu; Olivia Plana; Joan Montero; Kristen E Stevenson; Prakash Rao; Raga Vadhi; Michael Andreeff; Philippe Armand; Karen K Ballen; Patrizia Barzaghi-Rinaudo; Sarah Cahill; Rachael A Clark; Vesselina G Cooke; Matthew S Davids; Daniel J DeAngelo; David M Dorfman; Hilary Eaton; Benjamin L Ebert; Julia Etchin; Brant Firestone; David C Fisher; Arnold S Freedman; Ilene A Galinsky; Hui Gao; Jacqueline S Garcia; Francine Garnache-Ottou; Timothy A Graubert; Alejandro Gutierrez; Ensar Halilovic; Marian H Harris; Zachary T Herbert; Steven M Horwitz; Giorgio Inghirami; Andrew M Intlekofer; Moriko Ito; Shai Izraeli; Eric D Jacobsen; Caron A Jacobson; Sébastien Jeay; Irmela Jeremias; Michelle A Kelliher; Raphael Koch; Marina Konopleva; Nadja Kopp; Steven M Kornblau; Andrew L Kung; Thomas S Kupper; Nicole R LeBoeuf; Ann S LaCasce; Emma Lees; Loretta S Li; A Thomas Look; Masato Murakami; Markus Muschen; Donna Neuberg; Samuel Y Ng; Oreofe O Odejide; Stuart H Orkin; Rachel R Paquette; Andrew E Place; Justine E Roderick; Jeremy A Ryan; Stephen E Sallan; Brent Shoji; Lewis B Silverman; Robert J Soiffer; David P Steensma; Kimberly Stegmaier; Richard M Stone; Jerome Tamburini; Aaron R Thorner; Paul van Hummelen; Martha Wadleigh; Marion Wiesmann; Andrew P Weng; Jens U Wuerthner; David A Williams; Bruce M Wollison; Andrew A Lane; Anthony Letai; Monica M Bertagnolli; Jerome Ritz; Myles Brown; Henry Long; Jon C Aster; Margaret A Shipp; James D Griffin; David M Weinstock
Journal:  Cancer Cell       Date:  2016-04-11       Impact factor: 31.743

10.  A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice.

Authors:  A Mupo; L Celani; O Dovey; J L Cooper; C Grove; R Rad; P Sportoletti; B Falini; A Bradley; G S Vassiliou
Journal:  Leukemia       Date:  2013-03-12       Impact factor: 11.528

View more
  6 in total

1.  Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).

Authors:  Warren Fiskus; Steffen Boettcher; Naval Daver; Christopher P Mill; Koji Sasaki; Christine E Birdwell; John A Davis; Koichi Takahashi; Tapan M Kadia; Courtney D DiNardo; Qi Jin; Yuan Qi; Xiaoping Su; Gerard M McGeehan; Joseph D Khoury; Benjamin L Ebert; Kapil N Bhalla
Journal:  Blood Cancer J       Date:  2022-01-11       Impact factor: 9.812

2.  EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML.

Authors:  Hala Skayneh; Batoul Jishi; Rita Hleihel; Maguy Hamie; Rana El Hajj; Carine Deleuze-Masquefa; Pierre-Antoine Bonnet; Marwan El Sabban; Hiba El Hajj
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

Review 3.  Venetoclax resistance: mechanistic insights and future strategies.

Authors:  Faustine Ong; Kunhwa Kim; Marina Y Konopleva
Journal:  Cancer Drug Resist       Date:  2022-05-06

Review 4.  Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure.

Authors:  Debora Capelli; Diego Menotti; Alessandro Fiorentini; Francesco Saraceni; Attilio Olivieri
Journal:  Cancers (Basel)       Date:  2022-09-02       Impact factor: 6.575

Review 5.  Targeted therapy in NPM1-mutated AML: Knowns and unknowns.

Authors:  Rong Wang; Pan Xu; Lin-Lin Chang; Shi-Zhong Zhang; Hong-Hu Zhu
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

Review 6.  Current status and future perspectives in targeted therapy of NPM1-mutated AML.

Authors:  Roberta Ranieri; Giulia Pianigiani; Sofia Sciabolacci; Vincenzo Maria Perriello; Andrea Marra; Valeria Cardinali; Sara Pierangeli; Francesca Milano; Ilaria Gionfriddo; Lorenzo Brunetti; Maria Paola Martelli; Brunangelo Falini
Journal:  Leukemia       Date:  2022-08-25       Impact factor: 12.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.